3 Years After Merger, Genentech (RHHBY) R&D Outshines That of Roche (RHHBY)'s

7/3/2012 7:02:16 AM

When Roche paid $46.8 billion in 2009 to gain full ownership of Genentech, fears were rife that the arrival of the Swiss men in suits would stifle the free-wheeling innovative culture at the California-based biotech. Three years on, however, the jeans-wearing scientists in San Francisco have proven they are the ones driving the drugs pipeline of the 116-year-old Basel-based pharma giant, casting a shadow over Roche's own research operations. Roche's four top-selling medicines in 2011 - Rituxan, Avastin, Herceptin and Lucentis - were all cooked up in Genentech's labs and accounted for 55 percent of total pharma sales last year.

Read at Reuters

Read at Genetic Engineering News

Read Article at

Related Companies

News Categories

• Reuters

• Genetic Engineering News

• Roche

• Genentech

• Biotech/Pharma - Industry

• Biotech/Pharma - Industry (World)